LV12291B - COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS FOR TREATMENT OF TRIPTASE ACTIVITY-RELATED DISEASES - Google Patents

COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS FOR TREATMENT OF TRIPTASE ACTIVITY-RELATED DISEASES Download PDF

Info

Publication number
LV12291B
LV12291B LVP-99-27A LV990027A LV12291B LV 12291 B LV12291 B LV 12291B LV 990027 A LV990027 A LV 990027A LV 12291 B LV12291 B LV 12291B
Authority
LV
Latvia
Prior art keywords
compound
alkylene
hetero
formula
independently
Prior art date
Application number
LVP-99-27A
Other languages
English (en)
Latvian (lv)
Other versions
LV12291A (lv
Inventor
Jeffrey Mark DENER
Elaine Yee-Lin KUO
Ken Duane Rice
Vivian Rucywen Wang
Wendy Beth YOUNG
Original Assignee
Arris Pharmaceutical Corporation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Arris Pharmaceutical Corporation filed Critical Arris Pharmaceutical Corporation
Publication of LV12291A publication Critical patent/LV12291A/xx
Priority to LVP-00-31A priority Critical patent/LV12459B/en
Priority to LVP-00-30A priority patent/LV12458B/en
Publication of LV12291B publication Critical patent/LV12291B/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D295/00Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/16Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms
    • C07D295/20Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms by radicals derived from carbonic acid, or sulfur or nitrogen analogues thereof
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D295/00Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/16Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms
    • C07D295/20Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms by radicals derived from carbonic acid, or sulfur or nitrogen analogues thereof
    • C07D295/215Radicals derived from nitrogen analogues of carbonic acid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/06Antiasthmatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D211/00Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/18Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D211/26Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by nitrogen atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D233/00Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/04Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D233/06Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to ring carbon atoms
    • C07D233/08Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to ring carbon atoms with alkyl radicals, containing more than four carbon atoms, directly attached to ring carbon atoms
    • C07D233/12Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to ring carbon atoms with alkyl radicals, containing more than four carbon atoms, directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D233/14Radicals substituted by oxygen atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
LVP-99-27A 1996-07-30 1999-02-18 COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS FOR TREATMENT OF TRIPTASE ACTIVITY-RELATED DISEASES LV12291B (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
LVP-00-31A LV12459B (xx) 1996-07-30 2000-02-25 Savienojums un farmaceitiskās kompozīcijas ar triptāzes aktivitātes izmaiņām saistītu slimību ārstēšanai
LVP-00-30A LV12458B (xx) 1996-07-30 2000-02-25 Savienojums un farmaceitiskās kompozīcijas ar triptāzes aktivitātes izmaiņām saistītu slimību ārstēšanai

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US2313996P 1996-07-30 1996-07-30
US89577297A 1997-07-17 1997-07-17
PCT/US1997/013422 WO1998004537A1 (en) 1996-07-30 1997-07-30 Novel compounds and compositions for treating diseases associated with tryptase activity

Publications (2)

Publication Number Publication Date
LV12291A LV12291A (lv) 1999-06-20
LV12291B true LV12291B (en) 2000-04-20

Family

ID=26696778

Family Applications (1)

Application Number Title Priority Date Filing Date
LVP-99-27A LV12291B (en) 1996-07-30 1999-02-18 COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS FOR TREATMENT OF TRIPTASE ACTIVITY-RELATED DISEASES

Country Status (17)

Country Link
EP (1) EP0934293A1 (xx)
JP (1) JP2001509787A (xx)
KR (1) KR20000029679A (xx)
CN (1) CN1073103C (xx)
AU (1) AU733621B2 (xx)
CA (1) CA2262542A1 (xx)
CZ (1) CZ29799A3 (xx)
EE (1) EE9900036A (xx)
FI (1) FI990171A (xx)
HU (1) HUP0003267A3 (xx)
LV (1) LV12291B (xx)
NO (1) NO990433L (xx)
NZ (1) NZ333713A (xx)
PL (1) PL331465A1 (xx)
SI (1) SI9720047A (xx)
SK (1) SK8599A3 (xx)
WO (1) WO1998004537A1 (xx)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6221914B1 (en) 1997-11-10 2001-04-24 Array Biopharma Inc. Sulfonamide bridging compounds that inhibit tryptase activity
AU2723099A (en) * 1998-02-06 1999-08-23 Byk Gulden Lomberg Chemische Fabrik Gmbh Tryptase inhibitors
PT1060175E (pt) * 1998-02-06 2005-03-31 Max Planck Ges Ford Wissenscha Inibidores de triptase
IL141654A0 (en) * 1998-09-04 2002-03-10 Byk Gulden Lomberg Chem Fab Pyranose derivatives and pharmaceutical compositions containing the same
KR20020016942A (ko) 1999-08-10 2002-03-06 빅 굴덴 롬베르크 케미쉐 파브릭 게엠베하 디아조신-디온 유도체 및 이것의 트립타제 억제제로서 용도
EP1216236A1 (en) * 1999-09-14 2002-06-26 Byk Gulden Lomberg Chemische Fabrik GmbH Tryptase inhibitors
WO2001036386A1 (fr) * 1999-11-17 2001-05-25 Sumitomo Pharmaceuticals Co., Ltd. Traitement du diabete contenant un derive de dipiperazine
DE19955476A1 (de) * 1999-11-18 2001-05-23 Boehringer Ingelheim Pharma Bis-basische Verbindungen als Tryptase-Inhibitoren, Verfahren zu deren Herstellung sowie deren Verwendung als Arzneimittel
US6815557B2 (en) 1999-12-20 2004-11-09 Altana Pharma Ag Tryptase inhibitors
AU783217B2 (en) * 1999-12-20 2005-10-06 Altana Pharma Ag Tryptase inhibitors
PT1358182E (pt) * 2001-01-31 2004-12-31 Altana Pharma Ag Derivados de diazocinas e sua utilizacao como inibidores de triptase
AU2002253035B8 (en) 2001-02-21 2008-02-21 Altana Pharma Ag Tryptase inhibitors
DE60220504T2 (de) 2001-02-21 2008-02-14 Nycomed Gmbh Tryptasehemmer
WO2002074732A2 (en) * 2001-03-15 2002-09-26 Altana Pharma Ag Tryptase-inhibitors
US20040087792A1 (en) * 2001-03-15 2004-05-06 Thomas Martin Tryptase-inhibitors
ES2296956T5 (es) 2001-06-11 2011-07-12 Xenoport, Inc. Profármacos de análogos de gaba, composiciones y sus usos.
US6818787B2 (en) 2001-06-11 2004-11-16 Xenoport, Inc. Prodrugs of GABA analogs, compositions and uses thereof
US7186855B2 (en) 2001-06-11 2007-03-06 Xenoport, Inc. Prodrugs of GABA analogs, compositions and uses thereof
US8048917B2 (en) 2005-04-06 2011-11-01 Xenoport, Inc. Prodrugs of GABA analogs, compositions and uses thereof
DE60216920T2 (de) 2001-06-19 2007-11-15 Nycomed Gmbh Tryptase-inhibitoren
BRPI0517227B8 (pt) 2004-11-04 2021-05-25 Xenoport Inc comprimido oral de liberação prolongada do ácido 1-{[alfa-isobutanoiloxietoxi)carbonil]amino metil}-1-cicloexano acético, e, uso do comprimido
TWI432188B (zh) 2008-12-19 2014-04-01 Merz Pharma Gmbh & Co Kgaa 供治療發炎性皮膚疾病之1-胺基-烷基環己烷衍生物類
KR101335118B1 (ko) 2008-12-19 2013-12-05 메르츠 파마 게엠베하 운트 코. 카가아 비만 세포 매개 질환의 치료를 위한 1-아미노-알킬시클로헥산 유도체
FR3038605B1 (fr) 2015-07-06 2018-08-24 Universite Amiens Picardie Jules Verne Diamines primaires vicinales associees a des motifs chelateurs de metaux et/ou de radicaux libres, actives contre les stress carbonyle et oxydant et leur utilisation
JP7373191B2 (ja) * 2017-05-12 2023-11-02 国立研究開発法人理化学研究所 クラスa gpcr結合性化合物改変体

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4845242A (en) * 1987-04-28 1989-07-04 Georgia Tech Research Corporation Isocoumarins with basic substituents as serine proteases inhibitors, anticoagulants and anti-inflammatory agents
US5525623A (en) * 1993-03-12 1996-06-11 Arris Pharmaceutical Corporation Compositions and methods for the treatment of immunomediated inflammatory disorders
KR100309616B1 (ko) * 1993-03-12 2002-02-28 추후제출 면역중재된염증질환의치료를위한조성물및방법
WO1995032945A1 (en) * 1994-06-01 1995-12-07 Arris Pharmaceutical Corporation Compositions and methods for treating mast-cell mediated conditions
HUT77770A (hu) * 1994-09-23 1998-08-28 Axys Pharmaceuticals, Inc. Készítmény és eljárás hízósejtek által közvetített gyulladásos állapotok kezelésére
PL322409A1 (en) * 1995-03-24 1998-01-19 Arris Pharm Corp Reversible protease inhibitors
TW438591B (en) * 1995-06-07 2001-06-07 Arris Pharm Corp Reversible cysteine protease inhibitors

Also Published As

Publication number Publication date
NO990433L (no) 1999-03-25
CZ29799A3 (cs) 1999-06-16
LV12291A (lv) 1999-06-20
HUP0003267A3 (en) 2002-02-28
AU3967097A (en) 1998-02-20
KR20000029679A (ko) 2000-05-25
AU733621B2 (en) 2001-05-17
HUP0003267A2 (hu) 2001-06-28
FI990171A (fi) 1999-03-23
NO990433D0 (no) 1999-01-29
JP2001509787A (ja) 2001-07-24
EP0934293A1 (en) 1999-08-11
CN1226892A (zh) 1999-08-25
CA2262542A1 (en) 1998-02-05
PL331465A1 (en) 1999-07-19
WO1998004537A1 (en) 1998-02-05
FI990171A0 (fi) 1999-01-29
SI9720047A (sl) 1999-08-31
CN1073103C (zh) 2001-10-17
EE9900036A (et) 1999-08-16
SK8599A3 (en) 2000-03-13
NZ333713A (en) 2000-12-22

Similar Documents

Publication Publication Date Title
LV12291B (en) COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS FOR TREATMENT OF TRIPTASE ACTIVITY-RELATED DISEASES
AU686115B2 (en) Imidazo (I,2-a) pyridine derivatives as bradykinin antagonists, pharmaceuticals and processes for their preparation
SU1581221A3 (ru) Способ получени (4-пиперидинилметил- или гетеро)-пуринов или их фармацевтически приемлемых солей с кислотами, или стереоизомеров
US5607936A (en) Substituted aryl piperazines as neurokinin antagonists
US7932247B2 (en) M3 muscarinic acetylcholine receptor antagonists
US20090142279A1 (en) Novel m3 muscarinic acetylcholine receptor antagonists
CZ87097A3 (en) Preparation for therapy and therapeutical methods for treating inflammations mediated by mast cells
JP2007516212A (ja) 自己免疫疾患の処置における使用のための2−アミノピリミジンおよび2−アミノピリジン−4−カルバメート
WO2000027826A1 (de) Neue pyrimidine, deren herstellung und verwendung
US5574042A (en) Imidazo [1,2-a] pyridines and their pharmaceutical use
CZ20012562A3 (cs) Amidové sloučeniny
US6489327B1 (en) Tryptase inhibitors
DE4243858A1 (de) Aminosäurederivate, diese Verbindungen enthaltende Arzneimittel und Verfahren zu ihrer Herstellung
EP1057815B1 (en) Cyclic amide compounds
AU5625499A (en) Novel pyranoses
CA1305482C (en) Piperidine derivatives, their preparation and their application in therapy
ES2222259T3 (es) Inhibidores de triptasa.
US4792554A (en) Pyridine compounds, pharaceutical compositions, their use in allergy therapy
NZ506614A (en) Compounds for treating diseases associated with tryptase activity
JPH07330777A (ja) チエノ[3,2−d]ピリミジン−4−オン誘導体
MXPA99001105A (en) Novel compounds and compositions for treating diseases associated with tryptase activity
Kaur et al. Synthesis and antispasmodic activity evaluation of bis-(papaverine) analogues
LT4587B (lt) Nauji junginiai ir kompozicijos, skirti gydyti ligas, susijusias su triptazės aktyvumu
LV12459B (xx) Savienojums un farmaceitiskās kompozīcijas ar triptāzes aktivitātes izmaiņām saistītu slimību ārstēšanai
DE1445677C (de) Acylaminopyndine